Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation

Zhao, Yuzi; Pi, Jie; Liu, Lihua; Yan, Wenjie; Ma, Shufang; Li, Hong

doi:10.2147/cmar.s282529

Cited by 8 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clear cell renal cell carcinoma, inhibiting KIF11 increases the expression level of E-cadherin mRNA and decreases the mRNA level of mesenchymal markers, including N-cadherin and vimentin [118]. Similar results have been observed in ovarian cancer with an increasing level of ZEB-1, a transcriptional repressor of E-cadherin expression, instead of upregulated vimentin expression [134]. Apart from the E-cadherin/N-cadherin phenotypic switch, KIF11 can also regulate the expression of extrinsic factors to play roles in cell migration.…”

Section: Kif11 In Epithelial-mesenchymal Transition (Emt)supporting

confidence: 72%

Mitotic Functions and Characters of KIF11 in Cancers

Gao,

Lu,

Yang

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Mitosis mediates the accurate separation of daughter cells, and abnormalities are closely related to cancer progression. KIF11, a member of the kinesin family, plays a vital role in the formation and maintenance of the mitotic spindle. Recently, an increasing quantity of data have demonstrated the upregulated expression of KIF11 in various cancers, promoting the emergence and progression of cancers. This suggests the great potential of KIF11 as a prognostic biomarker and therapeutic target. However, the molecular mechanisms of KIF11 in cancers have not been systematically summarized. Therefore, we first discuss the functions of the protein encoded by KIF11 during mitosis and connect the abnormal expression of KIF11 with its clinical significance. Then, we elucidate the mechanism of KIF11 to promote various hallmarks of cancers. Finally, we provide an overview of KIF11 inhibitors and outline areas for future work.

show abstract

Section: Kif11 In Epithelial-mesenchymal Transition (Emt)supporting

confidence: 72%

Mitotic Functions and Characters of KIF11 in Cancers

Gao,

Lu,

Yang

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…The bioinformatic obtained results have been validated by an in vitro ovarian cancer model, represented by SKOV3 cell line: silencing of KIF11 results in a significant reduction of cell proliferation probably due to induction of apoptosis, as demonstrated by the increased activation of Caspase 3/7. Furthermore, as previously reported for other tumor models, KIF11 knockdown determines the effect not only on mitotic activity, but also on nonmitotic activity: siKIF11 reduced the invasion of SKOV3 cells and modified the expression levels of epithelial to mesenchymal transition genes, such as an upregulation of E-cadherin mRNA expression and a downregulation of N-cadherin and vimentin mRNA levels [ 54 ]. The bioinformatic results were also confirmed by Dong et al [ 53 ], suggesting that further investigation is required to better clarify Eg5 role in this malignancy.…”

Section: Eg5 In Tumor Onset and Progressionsupporting

confidence: 53%

Eg5 and Diseases: From the Well‐Known Role in Cancer to the Less‐Known Activity in Noncancerous Pathological Conditions

Ricci,

Carradori,

Cataldi

et al. 2024

Biochemistry Research International

View full text Add to dashboard Cite

Eg5 is a protein encoded by KIF11 gene and is primarily involved in correct mitotic cell division. It is also involved in nonmitotic processes such as polypeptide synthesis, protein transport, and angiogenesis. The scientific literature sheds light on the ubiquitous functions of KIF11 and its involvement in the onset and progression of different pathologies. This review focuses attention on two main points: (1) the correlation between Eg5 and cancer and (2) the involvement of Eg5 in noncancerous conditions. Regarding the first point, several tumors revealed an overexpression of this kinesin, thus pushing to look for new Eg5 inhibitors for clinical practice. In addition, the evaluation of Eg5 expression represents a crucial step, as its overexpression could predict a poor prognosis for cancer patients. Referring to the second point, in specific pathological conditions, the reduced activity of Eg5 can be one of the causes of pathological onset. This is the case of Alzheimer’s disease (AD), in which Aβ and Tau work as Eg5 inhibitors, or in acquired immune deficiency syndrome (AIDS), in which Tat‐mediated Eg5 determines the loss of CD4+ T‐lymphocytes. Reduced Eg5 activity, due to mutations of KIF11 gene, is also responsible for pathological conditions such as microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability (MCLRI) and familial exudative vitreous retinopathy (FEVR). In conclusion, this review highlights the double impact that overexpression or loss of function of Eg5 could have in the onset and progression of different pathological situations. This emphasizes, on one hand, a possible role of Eg5 as a potential biomarker and new target in cancer and, on the other hand, the promotion of Eg5 expression/activity as a new therapeutic strategy in different noncancerous diseases.

show abstract

“…A lot of studies also suggest that involvement of carcinogenesis in various cancers (lung, liver, and breast cancer) is due to highly expressed TOP2A thereby causing slow prognosis in patients [ 31 – 33 ]. TOP2A also promotes tumorigenesis in ovarian cancer which regulates the TGF- β /Smad pathway; the expression of TOP2A was also found to correlate with poor survival of ovarian cancer patients and platinum resistance [ 34 , 35 ]. Our results have shown that upregulation of TOP2A in tissues of ovarian cancer is linked with poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of Ovarian Cancer Patients

Wang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. One of the most usual gynecological state of tumor is ovarian cancer and is a major reason of gynecological tumor-related global mortality rate. There have been multiple risk elements related to ovarian cancer like the background of past cases associated with breast cancer or ovarian cancer, or excessive body weight issues, case history of smoking, and untimely menstruation or menopause. Because of unclear expressions, more than 70% of the ovarian cancer patient cases are determined during the early stage. Material and Methods. GSE38666, GSE40595, and GSE66957 were the three microarray datasets which were analyzed using GEO2R for screening the differentially expressed genes. GO, Kyoto Encyclopedia of Genes, and protein expression studies were performed for analysis of hub genes. Then, survival analysis was performed for all the hub genes. Results. From the dataset, a total of 199 differentially expressed genes (DEGs) were identified. Through the KEGG pathway study, it was noted that the DEGs are mainly linked with the AGE-RAGE signaling pathway, central carbon metabolism, and human papillomavirus infection. The survival analysis showed 4 highly expressed hub genes COL4A1, SDC1, CDKN2A, and TOP2A which correlated with overall survival in ovarian cancer patients. Moreover, the expression of the 4 hub genes was validated by the GEPIA database and the Human Protein Atlas. Conclusion. The results have shown that all 4 hub genes were found to be upregulated in ovarian cancer tissues which predict poor prognosis in patients with ovarian cancer.

show abstract

Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation

Cited by 8 publications

References 60 publications

Mitotic Functions and Characters of KIF11 in Cancers

Mitotic Functions and Characters of KIF11 in Cancers

Eg5 and Diseases: From the Well‐Known Role in Cancer to the Less‐Known Activity in Noncancerous Pathological Conditions

Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of Ovarian Cancer Patients

Contact Info

Product

Resources

About